The Potency Testing of Botulinum Neurotoxin Products

Pickett A. (2012). The botulinum toxin LD50 potency assay — another chapter, another mystery. ATLA 40, 221–223.

Bottrill K. (2003). Growing old disgracefully: The cosmetic use of botulinum toxin. ATLA 31, 381–391.

Balls M. (2003). Botulinum toxin testing in animals: The questions remain unanswered. ATLA 31, 611–615.

Balls M. (2010). Replacing the animal testing of botulinum toxin: Time to smooth out the wrinkles. ATLA 38, 1–2.

Balls M. , & Stephens M. (2006). Time for alternative action. Soap, Perfumery & Cosmetics 79, 32–33.

Straughan D. (2006). Progress in applying the Three Rs to the potency testing of botulinum toxin type A. ATLA 34, 305–313.

Bitz S. (2010). The botulinum neurotoxin LD50 test — problems and solutions. ALTEX 27, 114–116.

Sesardic D. , & Gaines-Das R. (2008). Alternatives to the LD50 assay for botulinum toxin potency testing: Strategies and progress towards refinement, reduction and replacement. AATEX 14, Special Issue, 581–585.

Adler S. , Bicker G. , Bigalke H. , Bishop C. , Blümel J. , Dressler D. , Fitzgerald J. , Gessler F. , Heuschen H. , Kegel B. , Luch A. , Milne C. , Pickett A. , Ratsch H. , Ruhdel I. , Sesardic D. , Stephens M. , Stiens G. , Thornton P.D. , Thürmer R. , Vey M. , Spielmann H. , Grune B. , & Liebsch M. (2010). The current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin potency testing. The report and recommendations of a ZEBET Expert Meeting. ATLA 38, 315–330.

ICCVAM (2008). Report on the ICCVAM-NICEATM/ ECVAM Scientific Workshop on Alternative Methods to Refine, Reduce or Replace the Mouse LD50 Assay for Botulinum Toxin Testing, 36 pp. Research Triangle Park, NC, USA: National Institutes of Health. Available at: http://iccvam.niehs.nih.gov/docs/biologics-docs/BoNTwkshprept.pdf (Accessed 20.11.12).

Anon. (2005). Test Method Nomination to the ICCVAM. Nomination of Alternative Methods to Replace the Mouse LD50 Assay for Botulinum Toxin Potency Testing, 37 pp. Washington, DC, USA: The Humane Society of the United States. Available at: http://iccvam.niehs.nih.gov/methods/biologics/botdocs/hsus.pdf (Accessed 20.11.12).

Singh A.K. , Stanker L.H. , & Sharma S.K. (2012). Botulinum neurotoxin: Where are we with detection technologies? Critical Reviews in Microbiology. [Epub ahead of print.]

Allergan, Inc. (2011). Allergan receives FDA approval for first-of-its-kind, fully in vitro, cell-based assay for BOTOX® and BOTOX® Cosmetic (onabotulinum toxinA). [Press release, 24.06.11]. Available at: http://agn.client.shareholder.com/releasedetail.cfm?ReleaseID=587234 (Accessed 22.11.12).

Spielmann H. (2011). Botox: FDA approves Allergan's first in vitro, cell-based potency assay CBPA. [AltTox Forum, 25.06.11]. Available at: http://forums.alttox.org/index.php?topic=683.0 (Accessed 22.11.12).

Balls M. , & Combes R. (2005). Validation at a crossroads. ATLA 33, 187.

Combes R. , & Balls M. (2003). How much flexibility is possible when validating new in vivo and in vitro toxicity test methods? ATLA 31, 225–232.

Fernandez-Salas E. , Wang J. , Garay P. , Wong L.S. , Hodges D. , & Aoki R. (2012). Immuno-based Botulinum Toxin Serotype A Activity Assays. US Patent 8198034. Available at: http://www.patentstorm.us/patents/8198034/fulltext.html (Accessed 22.11.12).

Zhu J. , Wang J. , Jacky B.P.S. , Hodges D.D. , & Fernandez-Salas E. (2012). Cells Useful for Immuno-based Botulinum Toxin Serotype A Activity Assays. US Patent Application 20120208271. Available at: http://www.patentstorm.us/applications/20120208271/fulltext.html (Accessed 22.11.12).

Ekong T.A.N. , Feavers I.M. , & Sesardic D. (1997). Recombinant SNAP-25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro. Microbiology 143, 3337–3347.

Gaines-Das R.E. , Heath A.B. , Martin H. , & Sesardic D. (1999). Validation of in vitro assays for botulinum toxin: A case study. Developments in Biological Standardization 101, 267–276.

Sesardic D. (2012). Bioassays for evaluation of medical products derived from bacterial toxins. Current Opinion in Microbiology 15, 310–316.

Whitemarsh R.C.M. , Strathman M.J. , Chase L.G. , Stankewicz C. , Tepp W.H. , Johnson E.A. , & Pellett S. (2012). Novel application of human neurons derived from induced pluripotent stem cells for highly sensitive botulinum neurotoxin detection. Toxicological Sciences 126, 426–435.

Chen S. , Karalewitz A.P. , & Barbieri J.T. (2012). Insights into the different catalytic activities of Clostridium neurotoxins. Biochemistry 51, 3941–3947.